account_balance
Investment manager · 13F filer · SEC CIK 1727492
Caligan Partners LP
Reported value$2.07Bas of Jun 30, 2026
Positions25 5 new, 4 sold out
Top 10 weight82.9%LQDA alone is 31%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
LQDALiquidia Corporation
31.2%
RVMDRevolution Medicines Inc
17.7%Added +19%
ABVXAbivax SA
10.0%Added +7%
PCVXVaxcyte Inc
6.1%Added +6%
EXELExelixis Inc
4.1%
TNGXTango Therapeutics Inc
3.8%Added +4%
AVTXAvalo Therapeutics Inc
2.8%Added +94%
XENEXenon Pharmaceuticals Inc
2.6%Trimmed −36%
ADMAAdma Biologics Inc
2.3%Added +20%
LBRX2.3%IMCR2.1%VRDN1.9%LQDALiquidia Corporation
31.2%
RVMD17.7%ABVXAbivax SA
10.0%Added +7%
PCVX6.1%EXEL4.1%TNGX3.8%AVTX2.8%XENE2.6%ADMA2.3%LBRX2.3%IMCR2.1%VRDN1.9%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
LQDA Liquidia Corporation 31.2% HeldRVMD Revolution Medicines Inc 17.7% Added +19%ABVX Abivax SA 10.0% Added +7%PCVX Vaxcyte Inc 6.1% Added +6%EXEL Exelixis Inc 4.1% HeldTNGX Tango Therapeutics Inc 3.8% Added +4%AVTX Avalo Therapeutics Inc 2.8% Added +94%XENE Xenon Pharmaceuticals Inc 2.6% Trimmed −36%ADMA Adma Biologics Inc 2.3% Added +20%LBRX Lb Pharmaceuticals Inc 2.3% HeldIMCR Immunocore Hldgs PLC 2.1% NewVRDN Viridian Therapeutics Inc 1.9% New
What changed